Kerri Fitzgerald

DocwireNews

A randomized, double-blind study published in the <a href="https://www.nature.com/articles/s41416-018-0340-2">British Journal of Cancer</a> compared the treatment regimen of paclitaxel plus trastuzumab biosimilar PF-05280014 or trastuzumab sourced from the European Union (trastuzumab-EU) as first-line therapy for human epidermal growth factor receptor 2-positive metastatic breast cancer. They found that both regimens resulted in similar objective response rates (ORRs; primary endpoint).This ongoing, international, randomized, double-blind, parallel-group study included 707 patients from 143 sites in 24 countries. Eligible patients were adult females with metastatic, histologically confirmed breast cancer with at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumours.Between April 4, 2014, and January 22, 2016, patients were randomized 1:1 to receive intravenous PF-05280014 plus paclitaxel (n=352) or trastuzumab-EU (n=355). PF-05280014 and trastuzumab-EU were administered weekly at a first dose of 4 mg/kg and subsequent dose of 2 mg/kg. Patients could change to a three-weekly regimen (6 mg/kg) at week 33. Patients continued treatment until disease progression. Paclitaxel was administered at a starting dose of 80 mg/m2 on days one, eight, and 15 of 28-day cycles for at least six cycles or until maximal benefit.At data cutoff (January 11, 2017), 536 randomized patients (75.8%) remained on study: 336 (47.5%) were still actively treated with PF-05280014 or trastuzumab-EU, while 200 (28.3%) had discontinued treatment but were being followed for survival. Disease progression was the primary reason for discontinuation of PF-05280014 (n=138; 39.2%) or trastuzumab-EU (n=143; 40.3).The risk ratio for ORR was 0.940 (95% CI, 0.842-1.049, falling within the prespecified equivalence margin of 0.80 to 1.25). The ORR was 62.5% (95% CI, 57.2-67.6) in the PF-05280014 group and 66.5% (95% CI, 61.3-71.4) in the trastuzumab-EU group, for a risk difference of &minus;4.0% (95% CI, &minus;11.0-3.1).At data cutoff, survival was similar between cohorts: Median progression-free survival (PFS) was 12.16 months in the PF-05280014 group and 12.06 months in the trastuzumab-EU group. The one-year PFS rate was 54% and 51%, respectively. The median overall survival (OS) was not reached in either group, and the one-year OS was 89.31% and 87.36%, respectively.Most patients in the safety cohort experienced one or more treatment-related adverse events (AEs), including 337 patients (96.6%) in the PF-05280014 group and 339 (96.0%) in the trastuzumab-EU. The most common AEs in both groups were alopecia, anemia, neutropenia, and peripheral sensory neuropathy. The researchers noted no differences in the incidences of AEs of special interest between either cohort.

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

Study Finds Trastuzumab Biosimilar Demonstrates Equivalence in Response Rates

Breast Cancer News

A randomized, double-blind study published in the British Journal of Cancer compared the treatment regimen of paclitaxel plus trastuzumab biosimilar PF-05280014 or trastuzumab ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe